Meridian Bioscience, Inc. (NASDAQ:VIVO) reached 33.1% versus a 1-year low price of $10.75. The stock was last seen 4.46% higher, reaching at $14.05 on Thursday, May 18, 2017. At recent session, the prices were hovering between $13.35 and $14.1. This company shares are 0.85% off its target price of $14.17 and the current market capitalization stands at $592.91M. The recent change has given its price a 2.5% lead over SMA 50 and -29.25% deficit over its 52-week high. The stock witnessed 3.42% gains, 11.13% gains and -14.57% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found VIVO’s volatility during a week at 3.63% and during a month it has been found around 3.4%.Meridian Bioscience, Inc. (VIVO) Top Holders
Institutional investors currently hold around $567 million or 91.1% in VIVO stock. Look at its top three institutional owners. Brown Capital Management Llc owns $76.44 million in Meridian Bioscience, Inc., which represents roughly 12.89% of the company’s market cap and approximately 13.48% of the institutional ownership. Similar statistics are true for the second largest owner, Blackrock Inc., which owns 5,142,223 shares of the stock are valued at $69.16 million. The third largest holder is Vanguard Group Inc, which currently holds $49.56 million worth of this stock and that ownership represents nearly 8.36% of its market capitalization.Meridian Bioscience, Inc. 13F Filings
At the end of 03/31/2017 reporting period, 97 institutional holders increased their position in Meridian Bioscience, Inc. (NASDAQ:VIVO) by some 9,563,254 shares, 81 decreased positions by 4,824,458 and 26 held positions by 27,776,566. That puts total institutional holdings at 42,164,278 shares, according to SEC filings. The stock grabbed 24 new institutional investments totaling 960,438 shares while 36 institutional investors sold out their entire positions totaling 2,990,828 shares.
Multiple company employees have indulged in significant insider trading. Meridian Bioscience, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Exec VP, CFO LUEKE MELISSA has acquired 4,000 shares of Meridian Bioscience, Inc. (VIVO) in trading session dated Feb. 02, 2017. These shares are worth $50,360 and were traded at $12.59 each. The SEC filing shows that BALDINI LAWRENCE performed a purchase of 4,000 shares. The EVP, Pres Global Operations added these shares by way of transaction on Jan. 26, 2017. The company’s shares were assimilated at $12.7 per share worth to an investment of some $50,800 on account of BALDINI LAWRENCE.
EVP, Research & Development, Elagin Vecheslav A, sold 7,883 common shares of Meridian Bioscience, Inc. (VIVO) in the open market. In a transaction dated Dec. 02, 2016, the shares were put up for sale at an average price of $17.3, raking in a sum of $136,376. After this sale, 53,003 common shares of VIVO are directly owned by the insider, with total stake valued at $744,692.
In the transaction dated Nov. 30, 2016, the great number of shares acquired came courtesy the Director; Ellingwood Dwight E added a total of 1,020 shares at an average price of $17.12, amounting to approximately $17,462. The insider now directly owns 7,000 shares worth $98,350.Meridian Bioscience, Inc. (VIVO) Analyst Guide
Several analysts have released their opinion on Meridian Bioscience, Inc. (NASDAQ:VIVO), with 0 analysts believing it is a strong buy. Whereas 4 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 2 strong sell ratings, collectively assigning a 3.67 average brokerage recommendation.